Bovine adrenal medulla peptide 8-22 compounds and methods of use thereof for treating pain

Patent metadata

Field	Value
Publication number	US-11718646-B2
Application number	US-202017121869-A
Country	US
Kind code	B2
Filing date	Dec 15, 2020
Priority date	Nov 9, 2015
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

First claim

What is claimed is:

1. A composition comprising a bovine adrenal medulla peptide 8-22 (BAMS-22) peptide coupled to a lipid anchor through a synthetic linker, wherein:
the BAMS-22 peptide comprises the amino acid sequence of SEQ ID NO: 1; or
the BAMS-22 peptide comprises an amino acid modification selected from a M to A substitution at position 15 of SEQ ID NO: 1 (M15A), and a Y to W substitution at position 17 of SEQ ID NO: 1 (Y17W); and
the synthetic linker and the lipid anchor are coupled to the C-terminus of the BAMS-22 peptide.

2. The composition of claim 1 , wherein the BAMS-22 peptide comprises M15A and Y17W amino acid modifications.

3. A pharmaceutical composition comprising a composition of claim 1 and a pharmaceutically acceptable carrier.

4. A method of treating neuropathic pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

5. The method of claim 4 , wherein the subject is a mammal.

6. A method of treating ocular pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

7. The method of claim 6 , wherein the subject is a mammal.

8. A method of treating ocular inflammation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

9. The method of claim 8 , wherein the subject is a mammal.

10. A method of treating dry eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

11. The method of claim 10 , wherein the subject is a mammal.

Assignees

• Tufts Medical Center
• Tufts College

Inventors

• Kopin Alan S
• Kumar Krishna
• Doyle Jamie Raudensky

Classifications

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/33

  derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin · CPC title

• A61K38/34

  Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin · CPC title

• A61K47/542

  Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title